Navigating the Complexity of BRAF Mutations in Non-small Cell Lung cancer: Current Insights and Future Prospects

Overview

Journal Multidiscip Respir Med

Specialty Pulmonary Medicine

Date 2024 Nov 15

PMID 39545749

Authors

Sufyan Ibrahim

Smita Shenoy

Ramya Kateel

Shreya Hegde

Amrita Parida

Lipsita Samantaray

Affiliations

Soon will be listed here.

Abstract

There are many challenges that are faced in the treatment of Non-Small Cell Lung Cancer (NSCLC) due to the complexities associated with the tumor. Association of different types of mutations are one of the major complexities. Among these mutations, BRAF mutations are significantly gathering more attention due to their impact on disease progression and therapeutic response. This review provides an analysis of the current understanding of BRAF mutations in NSCLC, focusing on the molecular intricacies, clinical implications, and therapeutic advancements. The article explores the diverse spectrum of BRAF mutations, highlighting the prevalence of specific mutations such as V600E and non-V600E alterations. The review also highlights the intricate signalling pathways influenced by BRAF mutations, shedding light on their role in tumorigenesis and metastasis. Therapeutically, we critically evaluate the existing targeted therapies tailored for BRAF-mutant NSCLC, addressing their efficacy, limitations, and emerging resistance mechanisms. Furthermore, we outline ongoing clinical trials and promising investigational agents that hold potential for reshaping the treatment of NSCLC. This review provides comprehensive current information about the role of BRAF mutations in NSCLC. Understanding the molecular diversity, clinical implications, and therapeutic strategies associated with BRAF-mutant NSCLC is crucial for optimizing patient outcomes and steering the direction of future research in this evolving field.

References

Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S . Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 395(10240):1835-1844. DOI: 10.1016/S0140-6736(20)30934-X. View

Gunderwala A, Cope N, Wang Z . Mechanism and inhibition of BRAF kinase. Curr Opin Chem Biol. 2022; 71:102205. PMC: 10396080. DOI: 10.1016/j.cbpa.2022.102205. View

Chan X, Singh A, Osman N, Piva T . Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. Int J Mol Sci. 2017; 18(7). PMC: 5536016. DOI: 10.3390/ijms18071527. View

Abdayem P, Planchard D . Ongoing progress in BRAF-mutated non-small cell lung cancer. Clin Adv Hematol Oncol. 2022; 20(11):662-672. View

Poulikakos P, Sullivan R, Yaeger R . Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Clin Cancer Res. 2022; 28(21):4618-4628. PMC: 9616966. DOI: 10.1158/1078-0432.CCR-21-2138. View

Riely G, Ahn M, Felip E, Ramalingam S, Smit E, Tsao A . Encorafenib plus binimetinib in patients with -mutant non-small cell lung cancer: phase II PHAROS study design. Future Oncol. 2021; 18(7):781-791. DOI: 10.2217/fon-2021-1250. View

Li H, Zhang Y, Xu Y, Huang Z, Cheng G, Xie M . Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer. Cell Death Dis. 2022; 13(12):1064. PMC: 9772302. DOI: 10.1038/s41419-022-05510-4. View

Smiech M, Leszczynski P, Kono H, Wardell C, Taniguchi H . Emerging Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks. Genes (Basel). 2020; 11(11). PMC: 7697059. DOI: 10.3390/genes11111342. View

Chu E, Wanat K, Miller C, Amaravadi R, Fecher L, Brose M . Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012; 67(6):1265-72. PMC: 4838029. DOI: 10.1016/j.jaad.2012.04.008. View

10.

Chen D, Zhang L, Huang J, Liu K, Chuai Z, Yang Z . BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2014; 9(6):e101354. PMC: 4076330. DOI: 10.1371/journal.pone.0101354. View

11.

Prabhash K . Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update. South Asian J Cancer. 2019; 8(1):1-17. PMC: 6348782. DOI: 10.4103/sajc.sajc_227_18. View

12.

Mezquita L, Oulhen M, Aberlenc A, Deloger M, Aldea M, Honore A . Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer. Br J Cancer. 2024; 130(4):682-693. PMC: 10876548. DOI: 10.1038/s41416-023-02535-0. View

13.

Martinez Fiesco J, Durrant D, Morrison D, Zhang P . Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding. Nat Commun. 2022; 13(1):486. PMC: 8789793. DOI: 10.1038/s41467-022-28084-3. View

14.

Janzic U, Shalata W, Szymczak K, Dziadziuszko R, Jakopovic M, Mountzios G . Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations. Int J Mol Sci. 2023; 24(16). PMC: 10454089. DOI: 10.3390/ijms241612840. View

15.

Abravanel D, Nishino M, Sholl L, Ambrogio C, Awad M . An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib. J Thorac Oncol. 2018; 13(8):e131-e133. PMC: 7102421. DOI: 10.1016/j.jtho.2018.03.026. View

16.

Niemantsverdriet M, Schuuring E, Ter Elst A, van der Wekken A, van Kempen L, van den Berg A . KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC. J Thorac Oncol. 2018; 13(12):e249-e251. DOI: 10.1016/j.jtho.2018.07.103. View

17.

Sullivan R, Weber J, Patel S, Dummer R, Carlino M, Tan D . A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with -mutant Solid Tumors. Clin Cancer Res. 2020; 26(19):5102-5112. DOI: 10.1158/1078-0432.CCR-19-3550. View

18.

Owsley J, Stein M, Porter J, In G, Salem M, ODay S . Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood). 2020; 246(1):31-39. PMC: 7797994. DOI: 10.1177/1535370220959657. View

19.

Tan L, Tran B, Tie J, Markman B, Ananda S, Tebbutt N . A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study. Clin Cancer Res. 2023; 29(6):1017-1030. PMC: 10011885. DOI: 10.1158/1078-0432.CCR-22-3094. View

20.

Lazar R, Fischbach C, Schott R, Somme L . Outcomes of non-small cell lung cancer patients with non-V600E mutations: a series of case reports and literature review. Front Oncol. 2024; 14:1307882. PMC: 11004365. DOI: 10.3389/fonc.2024.1307882. View